NIAID announces new human immunology research awards to help fight emerging infectiou...(the next five years under the IMVC progr...),Health

• Glen Barber, Ph.D., University of Miami School of Medicine
• Thomas Braciale, M.D., Ph.D., University Of Virginia, Charlottesville
• David Brooks, Ph.D., University of California Los Angeles
• Michael Gale, Ph.D., University of Washington School of Medicine, Seattle
• Douglas Hooper, Ph.D., Thomas Jefferson University, Philadelphia
• Curt Horvath, Ph.D., Northwestern University, Evanston, Ill.
• Jae Jung, Ph.D., University of Southern California, Los Angeles
• Robert Mason, M.D., National Jewish Medical and Research Center, Denver
• Andrew Mellor, Ph.D., Medical College of Georgia, Augusta
• Elke Muehlberger, Ph.D., Boston University School of Medicine
• Luis Sigal, Ph.D., Fox Chase Cancer Center, Philadelphia
• E. John Wherry, Ph.D., The Wistar Institute, Philadelphia
• Yiping Yang, M.D., Ph.D., Duke University Medical Center, Durham, N.C.
• Allan Zajac, Ph.D., University of Alabama at Birmingham, Birmingham

The following four awardees have received Recovery Act funding and will participate in the IMVC program for two years:

• Joan Durbin, M.D., Children's Research Institute, Columbus, Ohio
• Emilio Flano, Ph.D., Children's Research Institute, Columbus, Ohio
• Gregg Milligan, Ph.D., University of Texas Med. Branch, Galveston
• Thomas Moran, Ph.D., Mount Sinai School of Medicine, New York

"Developing vaccines and treatments for emerging pathogens continues to be a priority for NIAID," says Daniel Rotrosen, M.D., director of the NIAID Division of Allergy, Immunology and Transplantation. "The CCHI and IMVC programs will foster collaboration among many talented investigators working toward the common goal of understanding the human immune response to infectious diseases and developing more effective measures to prevent and treat infection."

'/>"/>